Dr Kieran Docherty
- Clinical Lecturer (Cardiovascular & Metabolic Health)
email:
Kieran.Docherty@glasgow.ac.uk
BHF Cardiovascular Research Centre, 126 University Place, Glasgow, G12 8TA
Biography
Kieran Docherty studied medicine at the University of Glasgow from 2005-2011. He is a Cardiology Specialist Registrar in the West of Scotland Deanery and is currently a Clinical Research Fellow at the Institute of Cardiovascular and Medical Sciences at the University of Glasgow. He is undertaking a PhD under the supervision of Professor John McMurray and Professor Mark Petrie examining the effects of neprilysin inhibition on left ventricular remodelling.
Research interests
- Heart failure
- myocardial infarction
- epidemiology
- clinical trials
Publications
2023
Docherty, K. F. et al. (2023) The effect of omecamtiv mecarbil in hospitalized patients as compared with outpatients with HFrEF: an analysis of GALACTIC-HF. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2023.08.020) (In Press)
Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)
Docherty, K. F. (2023) SGLT2 inhibitors and iron: more than meets the eye. JACC: Heart Failure, (Accepted for Publication)
Docherty, K. F. , Jackson, A. M., Macartney, M., Campbell, R. T., Petrie, M. C. , Pfeffer, M. A., McMurray, J. J.V. and Jhund, P. S. (2023) Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25(8), pp. 1213-1224. (doi: 10.1002/ejhf.2965) (PMID:37401485)
Docherty, K. F. , Lam, C. S.P., Rakisheva, A., Coats, A. J.S., Greenhalgh, T., Metra, M., Petrie, M. C. and Rosano, G. M.C. (2023) Heart failure diagnosis in the general community - who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 25(8), pp. 1185-1198. (doi: 10.1002/ejhf.2946) (PMID:37368511)
Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)
Curtain, J. P. et al. (2023) Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11(7), pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012) (PMID:37407154)
Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)
Yeoh, S. E. et al. (2023) Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF. Circulation, 147(22), pp. 1670-1683. (doi: 10.1161/CIRCULATIONAHA.122.063327) (PMID:37039015) (PMCID:PMC10212584)
Chatur, S. et al. (2023) Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.2912) (PMID:37210608) (Early Online Publication)
Campbell, R. T. and Docherty, K. F. (2023) Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance? European Heart Journal, (doi: 10.1093/eurheartj/ehad209) (PMID:37160825) (Early Online Publication)
Talha, K. M. et al. (2023) Potential global impact of sodium‐glucose cotransporter‐2 inhibitors in heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.2864) (Early Online Publication)
Butt, J. H. et al. (2023) Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11(4), pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014) (PMID:36881399)
Butt, J. H. et al. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)
Adamson, C. et al. (2023) IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11(3), pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004) (PMID:36592046)
Docherty, K. F. and Jhund, P. S. (2023) A welcome ‘failure’ of gliflozins: blood pressure reduction in heart failure. European Heart Journal, 44(5), pp. 408-410. (doi: 10.1093/eurheartj/ehac712) (PMID:36514970)
Docherty, K. F. et al. (2023) Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B ‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure, 25(2), pp. 248-259. (doi: 10.1002/ejhf.2763) (PMID:36597719)
Lee, M. M.Y. , Campbell, R. T., Claggett, B. L., Lewis, E. F., Docherty, K. F. , Lindner, M., Liu, J., Solomon, S. D., McMurray, J. J.V. and Platz, E. (2023) Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion. European Journal of Heart Failure, 25(1), pp. 54-60. (doi: 10.1002/ejhf.2699) (PMID:36161429) (PMCID:PMC9892176)
2022
Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)
Mc Causland, F. R. et al. (2022) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, (doi: 10.1001/jamacardio.2022.4210) (PMID:36326604)
Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61(11), pp. 4374-4383. (doi: 10.1093/rheumatology/keac072) (PMID:35136973)
Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450) (PMCID:PMC9715817)
Docherty, K. F. et al. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, 146(13), pp. 980-994. (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (PMCID:PMC9508991)
Vaduganathan, M. et al. (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400(10354), pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5) (PMID:36041474)
Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)
Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)
Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)
Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)
Lewis, G. D. et al. (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction. JAMA: Journal of the American Medical Association, 328(3), pp. 259-269. (doi: 10.1001/jama.2022.11016) (PMID:35852527)
Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)
McDowell, K. and Docherty, K. F. (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)
Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)
McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)
McMurray, J. J.V. and Docherty, K. F. (2022) Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45(S1), S26-S30. (doi: 10.1002/clc.23847)
Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)
Jhund, P. S. , Docherty, K. F. and McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)
Lee, M. M.Y. , Docherty, K. F. and Jhund, P. S. (2022) Sodium–glucose co-transporter-2 inhibitors. In: Clark, A. L., Gardner, R. S. and McDonagh, T. A. (eds.) Oxford Textbook of Heart Failure (2 edn). Oxford University Press, pp. 637-644. ISBN 9780198766223 (doi: 10.1093/med/9780198766223.003.0051)
Lewis, G. D. et al. (2022) Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF. Circulation: Heart Failure, 15(5), e008970. (doi: 10.1161/CIRCHEARTFAILURE.121.008970) (PMID:35236099)
Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)
Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004)
Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)
Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)
Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)
Docherty, K. F. and Petrie, M. C. (2022) Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108(4), pp. 312-320. (doi: 10.1136/heartjnl-2020-318658) (PMID:34127540)
Berg, D. D. et al. (2022) Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145(3), pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852) (PMID:34743554)
Rossing, P. et al. (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10(1), pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3) (PMID:34856173)
2021
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)
Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)
Lee, M. et al. (2021) Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. ESC Congress, 27-30 Aug 2021. (doi: 10.1093/eurheartj/ehab724.1043)
Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)
Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)
Petrie, M. C. , Lee, M. M.Y. and Docherty, K. F. (2021) Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), pp. 1256-1259. (doi: 10.1002/ejhf.2108) (PMID:33502794)
Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)
Espersen, C. et al. (2021) Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8(3), pp. 1784-1795. (doi: 10.1002/ehf2.13300) (PMID:33709520) (PMCID:PMC8120385)
Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)
Berg, D. D. et al. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)
McMurray, J. J.V. , Solomon, S. D., Docherty, K. F. and Jhund, P. S. (2021) The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 42(13), pp. 1199-1202. (doi: 10.1093/eurheartj/ehz916) (PMID:31898736) (PMCID:PMC8014512)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)
Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)
Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)
Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)
Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)
Inzucchi, S. E. et al. (2021) Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44(2), pp. 586-594. (doi: 10.2337/dc20-1675) (PMID:33355302)
Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)
Docherty, K. F. and Vaduganathan, M. (2021) OUTSTEP‐HF: re‐evaluating the role of physical activity measures in drug and device development in heart failure. European Journal of Heart Failure, 23(1), pp. 136-139. (doi: 10.1002/ejhf.2106) (PMID:33480140)
McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)
2020
Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)
Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)
Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)
McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)
Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)
Docherty, K. F. , Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)
Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)
Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)
Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)
Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)
Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)
Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)
Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)
2019
McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)
Docherty, K. F. and McMurray, J. J.V. (2019) PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115(13), e136-e139. (doi: 10.1093/cvr/cvz223) (PMID:31497841)
Platz, E. et al. (2019) Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7(10), pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008) (PMID:31582107)
Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)
McMurray, J. J.V. and Docherty, K. F. (2019) Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74(7), pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008) (PMID:31416534)
Dewan, P. , Docherty, K. F. and McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)
Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)
Docherty, K. F. and McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)
2018
Docherty, K. F. and Jhund, P. S. (2018) Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early? Heart, 104(22), pp. 1812-1813. (doi: 10.1136/heartjnl-2018-313371) (PMID:29760244)
Docherty, K. F. , Jhund, P. S. and McMurray, J. J.V. (2018) Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379(5), pp. 491-492. (doi: 10.1056/NEJMc1806519) (PMID:30070094)
2017
Docherty, K. F. , Campbell, R. T., Jhund, P. , Petrie, M. C. and McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)
2016
Wilson, M. R. , Docherty, K. F. and Gardner, R. S. (2016) Use of direct oral anticoagulants in thromboembolic disease. Prescriber, 27(8), pp. 15-22. (doi: 10.1002/psb.1487)
2014
Docherty, K. F. and Padmanabhan, S. (2014) Genomics and pharmacogenomics of lipid-lowering therapies. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Academic Press: London, pp. 715-746. ISBN 9780123868831 (doi: 10.1016/B978-0-12-386882-4.00031-1)
2013
Vuorio, A., Docherty, K.F. , Humphries, S.E., Kuoppala, J. and Kovanen, P.T. (2013) Statin treatment of children with familial hypercholesterolemia – trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis, 226(2), pp. 315-320. (doi: 10.1016/j.atherosclerosis.2012.10.032)
Articles
Docherty, K. F. et al. (2023) The effect of omecamtiv mecarbil in hospitalized patients as compared with outpatients with HFrEF: an analysis of GALACTIC-HF. Journal of Cardiac Failure, (doi: 10.1016/j.cardfail.2023.08.020) (In Press)
Yeoh, S. E. et al. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44(31), pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341) (PMID:37210742)
Docherty, K. F. (2023) SGLT2 inhibitors and iron: more than meets the eye. JACC: Heart Failure, (Accepted for Publication)
Docherty, K. F. , Jackson, A. M., Macartney, M., Campbell, R. T., Petrie, M. C. , Pfeffer, M. A., McMurray, J. J.V. and Jhund, P. S. (2023) Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25(8), pp. 1213-1224. (doi: 10.1002/ejhf.2965) (PMID:37401485)
Docherty, K. F. , Lam, C. S.P., Rakisheva, A., Coats, A. J.S., Greenhalgh, T., Metra, M., Petrie, M. C. and Rosano, G. M.C. (2023) Heart failure diagnosis in the general community - who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 25(8), pp. 1185-1198. (doi: 10.1002/ejhf.2946) (PMID:37368511)
Docherty, K. F. et al. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82(2), pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011) (PMID:37407113)
Curtain, J. P. et al. (2023) Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11(7), pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012) (PMID:37407154)
Butt, J. H. et al. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44(24), pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276) (PMID:37220172) (PMCID:PMC10290876)
Yeoh, S. E. et al. (2023) Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF. Circulation, 147(22), pp. 1670-1683. (doi: 10.1161/CIRCULATIONAHA.122.063327) (PMID:37039015) (PMCID:PMC10212584)
Chatur, S. et al. (2023) Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, (doi: 10.1002/ejhf.2912) (PMID:37210608) (Early Online Publication)
Campbell, R. T. and Docherty, K. F. (2023) Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance? European Heart Journal, (doi: 10.1093/eurheartj/ehad209) (PMID:37160825) (Early Online Publication)
Talha, K. M. et al. (2023) Potential global impact of sodium‐glucose cotransporter‐2 inhibitors in heart failure. European Journal of Heart Failure, (doi: 10.1002/ejhf.2864) (Early Online Publication)
Butt, J. H. et al. (2023) Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11(4), pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014) (PMID:36881399)
Butt, J. H. et al. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8(4), pp. 386-393. (doi: 10.1001/jamacardio.2022.5608) (PMID:36811901) (PMCID:PMC9947801)
Adamson, C. et al. (2023) IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11(3), pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004) (PMID:36592046)
Docherty, K. F. and Jhund, P. S. (2023) A welcome ‘failure’ of gliflozins: blood pressure reduction in heart failure. European Heart Journal, 44(5), pp. 408-410. (doi: 10.1093/eurheartj/ehac712) (PMID:36514970)
Docherty, K. F. et al. (2023) Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B ‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure, 25(2), pp. 248-259. (doi: 10.1002/ejhf.2763) (PMID:36597719)
Lee, M. M.Y. , Campbell, R. T., Claggett, B. L., Lewis, E. F., Docherty, K. F. , Lindner, M., Liu, J., Solomon, S. D., McMurray, J. J.V. and Platz, E. (2023) Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion. European Journal of Heart Failure, 25(1), pp. 54-60. (doi: 10.1002/ejhf.2699) (PMID:36161429) (PMCID:PMC9892176)
Yang, M. et al. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24(12), pp. 2307-2319. (doi: 10.1002/ejhf.2722) (PMID:36342375)
Mc Causland, F. R. et al. (2022) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, (doi: 10.1001/jamacardio.2022.4210) (PMID:36326604)
Sun, G. et al. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61(11), pp. 4374-4383. (doi: 10.1093/rheumatology/keac072) (PMID:35136973)
Ferreira, J. P., Claggett, B. L., Docherty, K. F. , Jhund, P. S. , Zannad, F., Solomon, S. D. and McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9(5), pp. 3655-3658. (doi: 10.1002/ehf2.13731) (PMID:35799450) (PMCID:PMC9715817)
Docherty, K. F. et al. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, 146(13), pp. 980-994. (doi: 10.1161/CIRCULATIONAHA.122.060511) (PMID:35971840) (PMCID:PMC9508991)
Vaduganathan, M. et al. (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400(10354), pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5) (PMID:36041474)
Jhund, P. S. et al. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28(9), pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4) (PMID:36030328) (PMCID:PMC9499855)
Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)
Butt, J. H. et al. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10(8), pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009) (PMID:35902157)
Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 146(4), pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851) (PMID:35877829)
Lewis, G. D. et al. (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction. JAMA: Journal of the American Medical Association, 328(3), pp. 259-269. (doi: 10.1001/jama.2022.11016) (PMID:35852527)
Shen, L. et al. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43(27), pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210) (PMID:35467706)
McDowell, K. and Docherty, K. F. (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8(4), pp. 371-373. (doi: 10.1093/ehjqcco/qcab088) (PMID:34921601) (PMCID:PMC9170565)
Butt, J. H. et al. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175(6), pp. 820-830. (doi: 10.7326/m21-4776) (PMID:35467935)
McDowell, K. et al. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24(6), pp. 1066-1076. (doi: 10.1002/ejhf.2433) (PMID:35064721)
McMurray, J. J.V. and Docherty, K. F. (2022) Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45(S1), S26-S30. (doi: 10.1002/clc.23847)
Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)
Jhund, P. S. , Docherty, K. F. and McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7(5), p. 570. (doi: 10.1001/jamacardio.2021.6032) (PMID:35234820)
Lewis, G. D. et al. (2022) Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF. Circulation: Heart Failure, 15(5), e008970. (doi: 10.1161/CIRCHEARTFAILURE.121.008970) (PMID:35236099)
Yeoh, S. E. et al. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10(5), pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019) (PMID:35483792)
Docherty, K. F. et al. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2(2), pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004)
Butt, J. H. et al. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24(3), pp. 513-525. (doi: 10.1002/ejhf.2381) (PMID:34766424)
Curtain, J. P. et al. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24(3), pp. 551-561. (doi: 10.1002/ejhf.2419) (PMID:34969175)
Lee, M. M.Y. et al. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8(2), pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138) (PMID:33337478) (PMCID:PMC7799280)
Docherty, K. F. and Petrie, M. C. (2022) Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108(4), pp. 312-320. (doi: 10.1136/heartjnl-2020-318658) (PMID:34127540)
Berg, D. D. et al. (2022) Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145(3), pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852) (PMID:34743554)
Rossing, P. et al. (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10(1), pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3) (PMID:34856173)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)
Docherty, K. F. et al. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6(11), pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632) (PMID:34319398)
Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)
Curtain, J. P. et al. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42(36), pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560) (PMID:34448003) (PMCID:PMC8455345)
Petrie, M. C. , Lee, M. M.Y. and Docherty, K. F. (2021) Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23(8), pp. 1256-1259. (doi: 10.1002/ejhf.2108) (PMID:33502794)
Docherty, K. F. et al. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144(3), pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892) (PMID:33983794)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6(6), pp. 678-689. (doi: 10.1001/jamacardio.2021.0379) (PMID:33787831)
Espersen, C. et al. (2021) Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8(3), pp. 1784-1795. (doi: 10.1002/ehf2.13300) (PMID:33709520) (PMCID:PMC8120385)
Jhund, P. S. et al. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143(20), pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659) (PMID:33832352) (PMCID:PMC8126492)
Berg, D. D. et al. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6(5), pp. 499-507. (doi: 10.1001/jamacardio.2020.7585) (PMID:33595593)
McMurray, J. J.V. , Solomon, S. D., Docherty, K. F. and Jhund, P. S. (2021) The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 42(13), pp. 1199-1202. (doi: 10.1093/eurheartj/ehz916) (PMID:31898736) (PMCID:PMC8014512)
Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23(4), pp. 601-613. (doi: 10.1002/ejhf.2124) (PMID:33594755)
Dewan, P. et al. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23(4), pp. 632-643. (doi: 10.1002/ejhf.2083) (PMID:33368858) (PMCID:PMC8247863)
Docherty, K. F. et al. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23(4), pp. 617-628. (doi: 10.1002/ejhf.2132) (PMID:33615642)
Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation, 143(6), pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186) (PMID:33186500) (PMCID:PMC7864599)
Docherty, K. F. et al. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8(1), pp. 129-138. (doi: 10.1002/ehf2.13137) (PMID:33305513) (PMCID:PMC7835504)
Inzucchi, S. E. et al. (2021) Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44(2), pp. 586-594. (doi: 10.2337/dc20-1675) (PMID:33355302)
Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143(4), pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391) (PMID:33040613) (PMCID:PMC7834909)
Docherty, K. F. and Vaduganathan, M. (2021) OUTSTEP‐HF: re‐evaluating the role of physical activity measures in drug and device development in heart failure. European Journal of Heart Failure, 23(1), pp. 136-139. (doi: 10.1002/ejhf.2106) (PMID:33480140)
McMurray, J. J.V. and Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23(1), pp. 27-30. (doi: 10.1002/ejhf.2075) (PMID:33283384)
Ferreira, J. P. et al. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8(12), pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004) (PMID:33039448) (PMCID:PMC7720789)
Kristensen, S. L. et al. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22(12), pp. 2370-2379. (doi: 10.1002/ejhf.1972) (PMID:32720404)
Docherty, K. et al. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43(11), pp. 2878-2881. (doi: 10.2337/dc20-1402) (PMID:33082245)
McEwan, P., Darlington, O., McMurray, J. J.V. , Jhund, P. S. , Docherty, K. F. , Böhm, M., Petrie, M. C. , Bergenheim, K. and Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22(11), pp. 2147-2156. (doi: 10.1002/ejhf.1978) (PMID:32749733) (PMCID:PMC7756637)
Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142(17), pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480) (PMID:32883108) (PMCID:PMC7580857)
Docherty, K. F. , Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)
Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 41(36), pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496) (PMID:32820334) (PMCID:PMC7550197)
Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142(11), pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077) (PMID:32673497) (PMCID:PMC7664959)
Docherty, K. F. et al. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41(25), pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183) (PMID:32221582) (PMCID:PMC7327533)
Docherty, K. F. et al. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22(5), pp. 848-855. (doi: 10.1002/ejhf.1694) (PMID:31944496)
Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323(14), pp. 1353-1368. (doi: 10.1001/jama.2020.1906) (PMID:32219386) (PMCID:PMC7157181)
Docherty, K. F. et al. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22(3), pp. 528-538. (doi: 10.1002/ejhf.1682) (PMID:31849164)
Kosiborod, M. N. et al. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141(2), pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138) (PMID:31736335) (PMCID:PMC6964869)
McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)
Docherty, K. F. and McMurray, J. J.V. (2019) PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115(13), e136-e139. (doi: 10.1093/cvr/cvz223) (PMID:31497841)
Platz, E. et al. (2019) Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7(10), pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008) (PMID:31582107)
Kristensen, S. L., Rorth, R., Jhund, P. S. , Docherty, K. , Sattar, N. , Preiss, D. , Kober, L., Petrie, M. C. and McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7(10), pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9) (PMID:31422062)
McMurray, J. J.V. and Docherty, K. F. (2019) Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74(7), pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008) (PMID:31416534)
Dewan, P. , Docherty, K. F. and McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49(6), pp. 469-484. (doi: 10.4070/kcj.2019.0136) (PMID:31172710) (PMCID:PMC6554586)
Shen, L. et al. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7(5), pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006) (PMID:30981744)
Docherty, K. F. and McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124) (PMID:29891240)
Docherty, K. F. and Jhund, P. S. (2018) Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early? Heart, 104(22), pp. 1812-1813. (doi: 10.1136/heartjnl-2018-313371) (PMID:29760244)
Docherty, K. F. , Jhund, P. S. and McMurray, J. J.V. (2018) Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379(5), pp. 491-492. (doi: 10.1056/NEJMc1806519) (PMID:30070094)
Docherty, K. F. , Campbell, R. T., Jhund, P. , Petrie, M. C. and McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38(5), pp. 338-345. (doi: 10.1093/eurheartj/ehw427) (PMID:27742808)
Wilson, M. R. , Docherty, K. F. and Gardner, R. S. (2016) Use of direct oral anticoagulants in thromboembolic disease. Prescriber, 27(8), pp. 15-22. (doi: 10.1002/psb.1487)
Vuorio, A., Docherty, K.F. , Humphries, S.E., Kuoppala, J. and Kovanen, P.T. (2013) Statin treatment of children with familial hypercholesterolemia – trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis, 226(2), pp. 315-320. (doi: 10.1016/j.atherosclerosis.2012.10.032)
Book Sections
Lee, M. M.Y. , Docherty, K. F. and Jhund, P. S. (2022) Sodium–glucose co-transporter-2 inhibitors. In: Clark, A. L., Gardner, R. S. and McDonagh, T. A. (eds.) Oxford Textbook of Heart Failure (2 edn). Oxford University Press, pp. 637-644. ISBN 9780198766223 (doi: 10.1093/med/9780198766223.003.0051)
Docherty, K. F. and Padmanabhan, S. (2014) Genomics and pharmacogenomics of lipid-lowering therapies. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Academic Press: London, pp. 715-746. ISBN 9780123868831 (doi: 10.1016/B978-0-12-386882-4.00031-1)
Conference or Workshop Item
Lee, M. et al. (2021) Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. ESC Congress, 27-30 Aug 2021. (doi: 10.1093/eurheartj/ehab724.1043)
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Trends in the incidence, morbidity and mortality of heart failure associated with myocardial infarction in Scotland: 1986-2016
NHS Greater Glasgow and Clyde
2017 - 2018